Under construction – not a live service
Sign in
Taking people in ChinaPhase 2

Targeted Drug Before Radiation for EGFR-Mutant Lung Cancer That Cannot Be Removed by Surgery

Tests fumetinib with chemotherapy in adults with EGFR-mutant lung cancer that cannot be operated on.

Key facts

Who runs it
Peng Zhang
Where
Shanghai, ChinaSee the site
Trial code
Registry title
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
Status
Recruiting
Phase
Phase 2
People taking part
160 people, planned
Started
25 Nov 2025
Expected to end
25 Nov 2032
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Fumetinib combined platinum-based double chemotherapy
  • Concurrent Radiochemotherapy
Record updated
3 August 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with non-small cell lung cancer that has an EGFR sensitive mutation and cannot be removed by surgery at stage III. They must have had no earlier cancer treatment.

Age
18 years or older
Sex
All sexes can join
Disease stage
Non-small cell lung cancer, stage II-IIIA (TNM Staging, Version 8), with no spread to other parts of the body
Earlier treatment
Cannot have had any cancer treatment for non-small cell lung cancer before, including surgery, radiotherapy, chemotherapy, targeted drugs or experimental treatment
Biomarker or test result
EGFR sensitive mutation confirmed by needle biopsy

Main reasons for not taking part

  • Any earlier systemic cancer treatment for non-small cell lung cancer
  • Unstable serious illness, such as active infection, uncontrolled high blood pressure or recent heart attack
  • HIV carrier
  • Current or past interstitial lung disease
  • Pregnancy or breastfeeding

The registry criteria, word for word

Show all 21 criteriaShow less

Who can take part

  • NSCLC patient with EGFR sensitive mutation as confirmed by needle biopsy
  • At stage II-IIIA (TNM Staging, Version 8) as identified by chest CT, PET-CT or/and EBUS
  • No systemic metastasis (confirmed by head MRI, whole body bone scan, PET-CT, liver and adrenal CT, etc.)
  • With the feasibility to receive radical surgery
  • Good lung function that could tolerate surgical treatment
  • Minimum age: 18 years
  • At least one measurable tumor foci (the longest diameter measured by CT shall be > 10 mm)
  • Other major organs shall function well (liver, kidney, blood system, etc.):
  • ECOG PS score shall be 0-1
  • The child-bearing female must undergo pregnancy test within 7 days before starting the treatment and the result shall be negative. Reliable contraceptive measures, such as intrauterine device, contraceptive pill and condom, shall be adopted during the trial and within 30 days after completion of the trial. The child-bearing male shall use condom for contraception during the trial and within 30 days after completion of the trial
  • The patient shall sign the Informed Consent Form

Who cannot take part

  • The patient suffers from any unstable systemic disease (including active infection, uncontrolled hypertension, unstable angina pectoris, angina pectoris that starts to attack within the last 3 months, congestive heart failure [≥ Grade II specified by New York Heart Association (NYHA)], cardiac infarction (6 months before enrollment), severe arrhythmia and liver, kidney or metabolic diseases that requires drug treatment
  • The patient had undergone other major systemic operations or suffered from severe trauma within 3 months before the trial
  • The patient has undergone any systemic anti-cancer treatment for NSCLC, including surgical treatment, local radiotherapy, cytotoxic drug treatment, targeted drug treatment and experimental treatment, etc
  • The patient is a carrier of HIV
  • The patient has had or is currently suffering from interstitial lung disease
  • The patient is allergic to befotertinib or its any excipients
  • The patient is allergic to bevacizumab or its any excipients
  • The patient is allergic to platinum-based double chemotherapy or its any excipients
  • There are any conditions under which the investigator considers the patient is not suitable to be enrolled
  • The female patient is in pregnancy or lactation period

Where in China

  • Shanghai Pulmonary HospitalShanghai, ChinaContact: Yue LiuTaking people

About the trial

What the trial wants to find out

The subjects of this study are patients with unresectable stage III non-small cell lung cancer (NSCLC) who have EGFR mutations.

The 2 groups in the trial

  • Fumetinib combined platinum-based double chemotherapyTreatment being tested
  • Concurrent RadiochemotherapyPlacebo, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC: a Single-center, Randomized Controlled Trial
Plain-language title
Targeted Drug Before Radiation for EGFR-Mutant Lung Cancer That Cannot Be Removed by SurgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 13 November 2026.
Record updated
3 August 2026